Transgenic mice expressing HIV-1 in immune cells
US6184436A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 3, 1999 |
| Grant date | Feb 6, 2001 |
| Priority date | — |
| Expiry date | Nov 3, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/008
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to a transgenic mouse to serve as a small animal model of AIDS which comprises at least a DNA sequence coding for HIV-1 nef or a HIV-1 DNA genome essentially consisting in entire HIV-1 coding sequences under the control of the human CD4 gene promoter flanked by the enhancer of the mouse CD4 gene for expression in T cells and in cells of monocyte/microphage lineage. There is also provided a method to screen for therapeutic agents for the treatment of AIDS, which comprises the steps of: a) administering the therapeutic agent to the mouse of the present invention; and b) determining the effects of the therapeutic agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.